Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based Stellar Pharmaceuticals has won CE mark approval to market NeoVisc viscosupplement therapy Single Dose (1 x 6ml) products in European Union (EU) countries.
Subscribe to our email newsletter
Both the Single Dose (1 x 6mL) and the original Triple Dose (3 x 2mL) are now available for sale in European Union.
NeoVisc Single Dose, a 6ml pre-filled syringe of sterile 1.0% sodium hyaluronate solution, is indicated for the temporary replacement of synovial fluid in osteoarthritic knee joints.
Stellar president and CEO Arnold Tenney said with the NeoVisc Triple Dose product already being sold throughout Eastern Europe, the addition of the NeoVisc Single Dose product provides flexibility and greater access for their distributors in these growing markets.
"In addition, the company is actively searching for new licensing opportunities in other large markets such as the US, China and Japan," Tenney said.